Tegaserod is a 5-HT4 agonist used for the management of constipation-predominant irritable bowel syndrome (IBS). It is currently marketed by Novartis under the trade names Zelnorm (in the US) or Zelmac (in other countries).
Tegaserod is a motility stimulant. Therapeutic effect is achieved through activation of 5-HT4 receptors of the enteric nervous system in the gastrointestinal tract. Tegaserod stimulates gastrointestinal motility and the peristaltic reflex, and possibly also reduces abdominal pain (Rossi, 2004).

Novartis - Zelnorm (tegaserod maleate) - Official US product website with information for patients and health professionals.
Meta Description: [ Learn how Zelnorm (tegaserod maleate) is different from fiber and laxatives and how it can help relieve the symptoms of Chronic Constipation and irritable bowel syndrome (IBS) ]
Zelnorm (tegaserod maleate) - Patient/consumer information provided by the U.S. Food and Drug Administration Center for Drug Evaluation and Research. Includes new label and FDA approval letter.
Meta Description: [ Zelnorm (tegaserod maleate) Information ]
Zelnorm - Novartis Pharmaceuticals Canada - Patient and prescribing information for this new medication (tegaserod hydrogen maleate) used to treat irritable bowel syndrome. Also includes related press releases and IBS links.
Meta Description: [ www.zelnorm.ca provides Canadians with prescribing and patient information about Zelnorm*, a prescription medication, from Novartis Pharmaceuticals Canada Inc. ]
| Market Withdrawal of Zelnorm (June 2007) | |